EU Approves Daraxonrasib for Pancreatic Cancer; Study Shows Survival Doubled
Researchers have identified daraxonrasib as an important clinical advance for patients with metastatic pancreatic cancer, a condition historically marked by extremely low survival rates.
While the drug has demonstrated the ability to inhibit tumor progression in clinical trials, experts emphasize that it is not a curative treatment.
- Clinical data indicate that daraxonrasib can double the survival duration for patients with metastatic disease who no longer respond to standard chemotherapy.
- The European Commission has granted accelerated approval for the medication, following a rapid scientific review by the European Medicines Agency (EMA).
- While the drug shows efficacy in targeting specific genetic mutations, oncologists caution that it is currently intended for patients who have already undergone prior treatment.
Clinical Performance and Survival Data
The therapeutic potential of daraxonrasib was highlighted at the EORTC-NCI-AACR Symposium 2026 in Barcelona, where researchers presented results showing that the drug, a RAS inhibitor, targets the protein responsible for continuous cell division in over 90 percent of pancreatic tumors, as reported by De Morgen.
In an international study involving 61 participants with advanced, metastatic disease, the combination of daraxonrasib and chemotherapy resulted in tumor shrinkage or stabilization in over 90 percent of patients, according to Newsmonkey –.
The survival outcomes represent a marked deviation from current standards of care. Patients receiving daraxonrasib following chemotherapy lived an average of 12.4 to 13.2 months, compared to 6.6 to 6.7 months for those receiving standard chemotherapy alone, according to data cited by Nieuwsblad, De Morgen, and HLN. Furthermore, Nieuwsblad reported that after one year of treatment, 53.2 percent of patients on the new therapy were alive, compared to 17 percent in the control group.
| Metric | Standard Chemotherapy | Daraxonrasib Combination |
|---|---|---|
| Median Survival | 6.6–6.7 months | 12.4–13.2 months |
| One-Year Survival Rate | 17% | 53.2% |
| Complete Response Rate | Low | ~8–8.2% |
Regulatory Approval and Access Challenges
The European Commission approved daraxonrasib for use in adults who have previously received treatment, utilizing an accelerated procedure that concluded in just over 100 days, HLN reported. This timeline is significantly faster than the standard 210-day evaluation period, reflecting the urgent medical need for this patient population. Despite this EU-level authorization, individual member states must now negotiate pricing and reimbursement with the manufacturer, Revolution Medicines.
Cost remains a primary barrier to immediate widespread implementation. According to Nieuwsblad, the daily medication is priced at approximately 38,000 euro per month, leading to estimated annual costs of 450,000 euro per patient, as noted by RTL.nl.
Marc Besselink of the Amsterdam UMC indicated that while the drug will eventually become available in the Netherlands, the current negotiation process between national health authorities and the manufacturer may take eight to sixteen months.
Limitations and Ongoing Research
Medical professionals caution against characterizing these findings as a permanent cure. “This study followed the patients for a maximum of 15 months. It is expected that the efficacy in most patients will eventually decrease over time,” Amy de Haar-Holleman of UZ Brussel told Nieuwsblad. She said that tumors often adapt to targeted therapies, and there is currently no such treatment that provides long-term, universal success for all patients.
Research is now shifting toward the drug’s utility for a broader patient demographic. Wungki Park of the Memorial Sloan Kettering Cancer Center, who led the research, stated, “We see not only that a higher percentage of tumors respond to the treatment, but also that the response is stronger and the disease remains under control for nearly twice as long,” as reported by De Morgen.
Ongoing studies are evaluating whether patients who have not yet received chemotherapy might benefit more from daraxonrasib monotherapy or a combination approach, according to Nieuwsblad.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- Autonomous Medical AI MIRA Achieves 88.9% Diagnostic Accuracy and Outperforms Specialists in Guideline Compliance
- Tuberculosis Delays Childhood Cancer Diagnosis and Disrupts Treatment Across Asia: A Cross-Sectional Survey
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)